+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06754098

Evaluating Oral Doxecitin and Doxribthymine for Adults with Thymidine Kinase 2 Deficiency An Open-Label, Single-Arm Treatment Study

Led by Cristina Domínguez González · Updated on 2026-09-17

15

Participants Needed

1

Research Sites

47 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effectiveness and safety of the combination of doxecitin and doxribthymine dTdC in adults with thymidine kinase 2 TK2 deficiency, a rare mitochondrial disorder causing progressive muscle weakness. This open-label, single-arm study focuses on adults with moderate to severe symptoms, including motor and respiratory involvement, who are followed at a specialized neuromuscular unit. Participants will receive oral doses of dTdC divided into three daily doses spaced about 6 to 8 hours apart. The treatment starts at 130 mgkgday per nucleoside and may be increased to 260 mgkgday after two weeks, then to a maximum of 400 mgkgday if tolerated. The study aims to enroll 10 to 15 participants who will be treated and monitored over a period of 24 months. Throughout the study, participants will visit regularly for assessments of motor function using several scales and tests, such as the Medical Research Council MRC scale, 6-minute walk test, and North Star Ambulatory Assessment. Respiratory function and use of ventilatory support will also be evaluated. Biomarkers like lactate and GDF15 will be monitored, along with safety through adverse event reporting. Treatment compliance and tolerability, especially diarrhea symptoms, will be closely observed.

CONDITIONS

Brief Title

Doxecitin and Doxribthymine in Adult Subjects With Thymidine Kinase 2 (TK2) Deficiency

Research Team

C

Cristina Domínguez González, Dra.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here